ReviewInternational journal of nanomedicine2026
Novel High-Atomic-Number Element and Nanoparticle-Based CT Contrast Agents: Advanced Design Strategies and Clinical Translational Barriers.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In clinical medicine, computed tomography (CT) contrast media serve as vital diagnostic adjuncts that substantially elevate tissue contrast and diagnostic precision. This review systematically summarizes the latest advances in CT contrast agent research, focusing on four key areas: novel molecular design and synthesis strategies, optimization of pharmacokinetics and imaging performance, expansion of clinical application fields, and safety management including strategies to address adverse reactions. Despite considerable progress, challenges remain in improving biocompatibility, reducing toxicity, and tailoring agents for specific diagnostic needs. By providing a comprehensive overview of current research hotspots and unresolved issues, this article defines a specific translational framework aimed primarily at contrast agent development for human clinical patients, while systematically assessing the physical and biological boundaries that bridge preclinical small animal models to human diagnostic workflows. Crucially, we highlight key unresolved milestones, specifically focusing on the critical clinical translational barriers of nanoparticle-based agents, including long-term reticuloendothelial organ retention risks and global supply chain constraints inherent to rare High-Atomic-Number (high-Z) minerals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.